

**REMARKS**

Applicants would like to thank the Examiner for the telephone conference of April 7, 2004 in which the Examiner indicated that the claims submitted with the Amendment filed on October 10, 2003 (a copy of which is enclosed) would be entered if submitted along with a Request for Continued Examination.

Accordingly, upon entry of the October 10, 2003 Amendment, claims 21-30 will be pending. No new matter is being presented.

**CONCLUSION**

On the basis of the foregoing amendments and remarks, Applicants respectfully submit that the pending claims are in condition for allowance. If a telephone conversation with Applicants' Attorney would expedite prosecution of the above-identified application, the Examiner is invited to call the undersigned at (617) 227-7400.

Date: April 15, 2004

LAHIVE & COCKFIELD, LLP  
Attorneys at Law

By



Cynthia L. Kanik, Ph.D.  
Reg. No. 37,320  
28 State Street  
Boston, MA 02109  
(617) 227-7400  
(617) 742-4214



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: David Thomas et al.

Serial No.: 09/773866

Filed: February 1, 2001

For: CD40-BINDING APC-ACTIVATING  
MOLECULES

Attorney Docket No.: PNJ-001

Group Art Unit: 1644

Examiner: Phillip Gambel

COPY

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 309882782 US, in an envelope addressed to: MS Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

October 10, 2003  
Date of Signature

By:   
Cynthia L. Kanik, Ph.D.  
Reg. No. 37, 320  
Attorney for Applicants

**AMENDMENT AND RESPONSE**

Dear Sir:

This is in response to the Office Action mailed from the United States Patent and Trademark Office on September 3, 2002 (Paper No. 7), for the above referenced patent application. A Petition to Revive and associated fee, as well as a paper and computer readable form of the Sequence Listing and a Supplemental Information Disclosure Statement, are being filed concurrently herewith.

Please amend the application as follows:

**Amendments to the Specification** begin on page 2 of this paper

**Amendments to the Claims** are reflected in the listing of claims which begins on page 6 of this paper.

**Remarks** begin on page 8 of this paper.

**Amendments to the Specification**

Please insert the Sequence Listing filed concurrently herewith.

Please replace the Title of the Invention at page 1, line 1, with the following amended title:

**INDUCTION OF CYTOTOXIC T LYMPHOCYTE RESPONSES USING  
ANTI-CD40 ANTIBODIES**

Please replace the paragraph at page 9, lines 10-15, with the following amended paragraph:

These antibodies and the method of making them are described in U.S. Patent No. 5,534,254 (Creative Biomolecules, Inc.). Different embodiments of bispecific antibodies described in the patent include linking single chain Fv with peptide couplers, including Ser-Cys, (Gly)<sub>4</sub>-Cys (SEQ ID NO: 1), (His)<sub>6</sub>-(Gly)<sub>4</sub>-Cys (SEQ ID NO: 2), chelating agents, and chemical or disulfide couplings including bismaleimidohexane and bismaleimidocaproyl.

Please replace the paragraph at page 12, lines 2-11, with the following amended paragraph:

The EBV-transformed B-cell line JY and the myeloid derived cell line THP1 were cultured in T75 culture flasks routinely in Iscove's modified Dulbecco's medium (IMDM) to which 50 [[]] $\mu$ g/ml gentamycin and 2% heat inactivated foetal calf serum was added ([[FCS]]) FCS; BioWithaker, Verviers, Belgium). The cells were cultured in a humidified incubator at 37°C and 5% CO<sub>2</sub>. Once or twice per week the cells were split (1/20 to 1/100). To store the cell line, ampoules were made containing 5-10 x 10<sup>6</sup>

cells/ml Hank's balanced salt solution (HBSS) supplemented with 20% [[FCSi]] FCS and 10% DMSO, and stored in [[the]] liquid nitrogen.

Please replace the paragraph at page 15, lines 11-18, with the following amended paragraph:

*3 x 10<sup>6</sup> THP-1 cells were first cultured for two days in 10 ml of IMDM + 2% of human type AB serum in the presence of 5 x 10<sup>2</sup> U/ml IFN-[[□]]γ. Next the IFN-[[g]]γ treated THP-1 cells were washed once in IMDM + 2% human type AB serum. 10<sup>4</sup> THP-1 cells per well per 96 [[w]] well plate [[well]] were cultured for two days in 120 μl of culture medium diluted 1:2 with hybridoma supernatant. As controls CD154-mCD8 was used at 40 [[□]]μg/ml maximum and 2x dilutions and LPS at 20 ng/ml maximum and 2x dilutions.*

Please replace the paragraph at page 15, line 20, to page 16, line 10, with the following amended paragraph:

ELISA plates were coated with mouse anti human IL-8 antibody (Serotec) at 5 μg/ml, 100 [[□]]μl/well for 2 hrs at room temperature on a plate shaker. The plates were then incubated with 1% BLOTTO for one hour on the plate shaker at room temperature. After four washings with PBS/Tween, 80 μl of supernatants harvested from the THP-1 plate were added to the ELISA plate. For the IL-8 standards[[:]], IL-8 was diluted with 1% BLOTTO to 1000 pg/ml, 300 pg/ml, 100 pg/ml, 30 pg/ml, 10 pg/ml, 3 pg/ml, and 1 pg/ml. The ELISA plates were incubated for one [[hr]] hour at room temperature on the plate shaker. After four washings with PBS/Tween, 100 μl/well mouse-anti IL-8 biotin conjugate (Serotec) was added at 1:1000 dilution in 1% BLOTTO and the plates were incubated for one hour at room temperature. After four washings with PBS/Tween, 100 [[□]]μl/well AMDX SA-HRP at 1:1000 dilution in 1% BLOTTO was added to the wells and the plates were incubated for 1 hour at room temperature on the plate shaker. After 4 washings with PBS/Tween, 100 [[□]]μl of TMB substrate was added to each well and the

plates were incubated for 30 minutes at room temperature on the plate shaker. The reaction was stopped by addition of 50  $\mu$ l/well of 0.2 M H<sub>2</sub>SO<sub>4</sub> and the plates were read with an ELISA reader at 450/590 nm.

Please replace the paragraph at page 18, line 26, to page 19, line 8, with the following amended paragraph:

To screen for antibodies with agonistic activity, the selected supernatants containing CD40 binding antibodies were subsequently tested for their ability to induce IL-8 production in the CD40 expressing monocytic cell line THP-1, which had been pre-incubated with IFN- $\gamma$ . ~~As shown in table 1, most~~ Most of the supernatants tested contained anti-CD40 antibodies[[,]] which displayed agonistic activity in this assay. Supernatants were arbitrarily subdivided into four different groups on the basis of their performance in the THP-1 assay (strong agonists with an OD of >2.000, intermediate agonists with an OD between 1.000-2.000, low agonists with an OD between 0.375-0.999 and non-agonists with an OD <0.375).

Please replace the paragraph at page 22, lines 5-24, with the following amended paragraph:

Anti-CD40 antibodies that synergize with cCD40L in the induction of CD40 mediated activation of DC most likely show co-binding with sCD40L to CD40 and thus do not display strong blocking of binding of sCD40L to CD40. To screen for such antibodies, the percentage of inhibition of sCD40L binding to CD40 on JY EBV transformed B cells by the monoclonal antibodies was tested. This analysis revealed that there was strong variation in the degree that the monoclonal antibodies could inhibit the binding of sCD40L to CD40. Some antibody samples almost completely inhibited sCD40L binding, whereas other antibody samples could only partially block sCD40L binding or had no effect at all (table 2). The results were confirmed in the reverse way for a limited number of clones by testing the inhibition caused by the anti-CD40 monoclonal antibodies of the binding of CD40-Fc to CD40L expressed on the membrane

of PMA + ionomycin activated CD4+ T cells. In this experiment clone 4 blocked binding of CD40-Fc to CD40L on the T cells for 88%, clone 7 and 64 for respectively 16% and 25%. Although there was no absolute correlation between the performance of the antibodies in the DC maturation and the THP-1 assay and their ability to block binding to CD40, all the clones that did not block this interaction were non-responders in both assays (data not shown).

**Abstract**

Please replace the Abstract with the amended Abstract provided herewith on a separate page.

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:****Claims 1-20 (Canceled)**

Claim 21 (New) A method of inducing an antigen specific cytotoxic T cell response comprising administering an antibody, or binding fragment thereof, that binds to CD40 on human antigen presenting cells (APC) without blocking binding of CD40L to CD40, wherein the antibody is capable of inducing an APC-mediated antigen specific human cytotoxic T lymphocyte response.

Claim 22 (New) The method of claims 21, wherein the antigen presenting cell is a monocyte derived dendritic cell.

Claim 23 (New) The method of claims 21, wherein the antibody is a monoclonal antibody or binding fragment thereof.

Claim 24 (New) The method of claims 21, wherein the monoclonal antibody is a chimeric, humanized, human, DEIMMUNISED™, or a single chain antibody.

Claim 25 (New) The method of claims 21, wherein the antibody is a bispecific antibody.

Claim 26 (New) The method of claim 25, wherein the bispecific antibody comprises a binding specificity for each of two different epitopes on CD40.

Claim 27 (New) The method of claim 25, wherein the bispecific antibody comprises a binding specificity for CD40 and a T cell determinant.

Claim 28 (New) The method of claim 27, wherein the T cell determinant is selected from the group consisting of 4-1BB and CD28.

Claim 29 (New) The method of claim 21, further comprising administering IFN- $\gamma$ .

Claim 30 (New) The method of claim 21, wherein the agonist anti-CD40 antibody is administered by injection.

**REMARKS**

Claims 12-20 have been canceled without prejudice to continued prosecution. New claims 21-30 have been added. Accordingly, upon entry of the present amendment, claims 21-30 will be pending.

The title and abstract have been amended to reflect the newly pending claims. In addition, various typographical errors have been corrected throughout the specification. The specification has been further amended to include the appropriate SEQ ID Nos and a paper copy of the sequence listing filed herewith.

Support for new claims 21-30 can be found throughout the specification and claims as originally filed. For example, support for claim 21 can be found at least at page 16, lines 11-20 and at pages 19-21. Support for claim 22 and 23 can be found at least at page 20, lines 12-28. Support for claims 24-29 can be found at least at pages 6-9, pages 17-19, and at page 21, lines 27-29. Support for claim 30 can be found at least at page 24, lines 6-21. Accordingly, no new matter has been added.

The claim cancellations requested herein should in no way be construed as acquiescence to any of the rejections and have been made solely to expedite prosecution of the application. Applicants reserve the right to pursue the claims as originally filed and/or prior to amendment herein in this or a separate application(s).

Applicants gratefully thank the Examiner for the courtesy of the interview held on June 25, 2003, with Applicants' attorney, during which the outstanding rejections of record were discussed. In particular, as noted on the Interview Summary, Applicants emphasized the lack of teaching in the prior art with respect to the use of agonistic anti-CD40 antibodies to induce antigen presenting cells (APCs)-mediated cytotoxic T lymphocyte (CTL) responses.

More specifically, the prior art fails to teach or suggest a non-blocking agonistic anti-CD40 antibody capable of inducing a CTL response. In fact, one of the few non-blocking anti-CD40 antibodies known in the prior art, mAb 5D12, had been shown to be antagonistic (*i.e.*, it inhibited CTL responses), not agonistic as presently claimed (*e.g.*, see Pasch et al., WO 02/11763, submitted herewith as Appendix A). Conversely, a number

of agonistic anti-CD40 antibodies known in the prior art had been shown to be blocking antibodies, such as mAb 5C11 taught by Zhou et al. (cited in the present Office Action), and MAb89 taught by Bjorck et al. (*Immunology* 83:430-437, submitted herewith as Appendix B). Thus, based on anti-CD40 mAbs known in the art at the time of the invention, one of ordinary skill in the art trying to generate an agonistic anti-CD40 antibody would have been motivated to have generated a blocking anti-CD40 antibody (not a non-blocking antibody, as presently claimed), since it was thought that the antibody must mimic the signal provided by the natural ligand, CD40L, which stimulates CTL responses.

Accordingly, Applicants' discovery that non-blocking anti-CD40 antibodies are capable of agonizing CTL responses was entirely unexpected. In addition, the use of non-blocking anti-CD40 antibodies provides a significant advantage in that it does not prevent natural CD40L-mediated immune responses from occurring. Thus, the claimed method of inducing a CTL response can be used as an additive therapy in the presence of CD40L, but also can stimulate CTL responses (i.e., be used therapeutically) in the absence of CD40L.

The following summary is provided to help highlight the novel and inventive aspects of the currently claimed invention:

Prior to Applicants' invention, it was understood in the art that the effector functions of CD8+ cytotoxic T cells (CTLs) are so destructive that naïve CD8+ cells require more co-stimulatory activity to induce differentiation into CTLs than do naïve CD4+ T cells which differentiate into T helper cells. Thus, differentiation of CD8+ cells into cytotoxic T cells was thought to occur in two ways. Certain virally infected dendritic cells express high levels of costimulatory molecules and induce CD8+ T cells to produce IL-2 which, in turn, drives the proliferation and eventual differentiation of these T cells into cytotoxic T cells. Alternatively, CD8+ activation by some viruses and other antigens, are thought to require the presence of CD4+ T helper cells. In these responses, both naïve CD8+ and CD4+ cells must recognize related antigens on the surface of the same antigen presenting cell. Recruitment and differentiation of the CD4+ T cell into a T helper cell results in activation of the antigen presenting cell to express higher levels of

costimulatory activity, thus enabling costimulation and differentiation of the CD8+ T cell. These two pathways are further illustrated in Appendix C.

In contrast, the present invention is based on finding that an antigen specific cytotoxic T cell response can be induced when naïve CD8+ T cells are contacted with antigen presenting cells that have been induced to mature by binding of agonist anti-CD40 antibodies. Moreover, as discovered by Applicants, agonist antibodies that do not block the binding of CD40L to CD40 are particularly effective in eliciting a cytotoxic T lymphocyte response. This finding was particularly unexpected in view of the prior art, which focused on the identification and use of anti-CD40 antibodies that mimic (i.e., compete with) CD40L for binding to CD40.

Accordingly, the currently presented claims are directed to methods of inducing a human cytotoxic T lymphocyte response by administering agonist anti-CD40 antibodies that do not block binding of CD40L to CD40. This surprising effect is clearly demonstrated by Applicants in the Examples provided in the present specification which describe working studies and corresponding data showing that maturation of antigen presenting cells can be induced using an agonist anti-CD40 antibody, *e.g.*, that does not interfere with CD40/CD40L interaction, and that these mature antigen presenting cells can induce activation of cytotoxic T lymphocytes in the absence of other components of the immune system, *e.g.*, helper T cells.

### ***Objections to the Specification***

The specification has been objected for failing to comply with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures as set forth in 37 CFR 1.821-1.825. Accordingly, Applicants have submitted herewith a paper and computer readable form of the sequence listing (1 page), containing sequences which were in the specification as originally filed, to be included in the specification part of the disclosure. In addition, the specification has been amended to include the appropriate sequence identifier numbers. No new matter has been added to the application.

The specification has also been objected to based on various typographical errors. Accordingly, the specification has been carefully reviewed by Applicants and amended to correct all typographical errors, and to remove inadvertent references to Tables 1 and 2. In addition, the Title of the Invention and Abstract of the Disclosure have been amended to reflect the invention as presently claimed. Accordingly, in view of the foregoing amendments to the specification, Applicants respectfully request withdrawal of these objections.

The abstract of the disclosure has been objected to based on the ground that it does adequately describe the claimed invention. Accordingly, an amended abstract has been provided on a separate page.

### ***Formal Drawings***

The drawings have been objected to for failing to comply with the 37 CFR 1.84. Applicants respectfully submit that corrected drawings will be submitted upon the receipt of a Notice of Allowability.

### ***Priority Date of the Claimed Invention***

The Examiner maintains that the previously pending claims were not entitled to the benefit of priority to USSN 60/178,934 based on the Examiner's assertion that the priority application does not provide written support for the term "non-professional human APCs," the phrase "induce phenotypical and functional maturation of monocytes derived dendritic cells," and for the limitations set forth in claims 6 and 7.

Applicants respectfully disagree. However, to expedite prosecution, the previously pending claims have been replaced with new claims 21-30. New claims 21-30 do not contain any of the language objected to. Therefore, the objection is now moot.

Notwithstanding, Applicants maintain that the limitations objected to by the Examiner are fully supported in the priority document as filed. Specifically, support for anti-CD40 molecules (e.g., antibodies) that "enhance the stimulatory effect of CD40L on CD40 positive cells" or "can simultaneously bind to CD40 with CD40L..." or "completely inhibit CD40L binding" can be found in original claims 3-5 of USSN

60/178,934. Moreover, the summary of the invention refers to “antigen presenting cells”, along with a description of both the phenotypic and functional characteristics of mature dendritic cells (i.e., professional APCs), for example, at pages 10 and 13.

Accordingly, at least for the foregoing reasons, Applicants respectfully submit that the previously claimed invention was entitled to the priority date of February 1, 2000, the filing date of USSN 60/178,934. It is also noted that this objection has not been made with respect to the presently pending claims.

***Rejections under 35 U.S.C. §112, first paragraph***

Claims 1-9 and 13 have been rejected on the ground that the disclosure does not reasonably convey to one of ordinary skill in the art that the inventor(s) had possession of the claimed invention at the time the application was filed. Specifically, the Examiner asserts that there is insufficient written description for “agonist anti-CD40 molecules” because the relevant identifying characteristics, such as structure or other physical and/or chemical characteristics of molecules, other than other than agonist anti-CD40 antibodies, are not set forth in the specification (Paper 7, page 4). Claims 1-9 and 13 also have been rejected on the ground that “the specification, while being enabling for ‘agonist anti-CD40 antibodies’ and ‘CD40 binding fragments thereof,’ as disclosed in the specification as filed, does not reasonably provide enablement for any ‘agonist anti-CD40 molecule.’” (Paper No. 7, page 7).

Applicants respectfully traverse these rejections. However, solely in the interest of expediting prosecution, claims 1-9 and 13 have been cancelled, thus rendering these rejections moot.

Applicants respectfully note that the presently claimed methods are drawn to the use of agonist anti-CD40 antibodies and/or binding fragments thereof (which the Examiner acknowledges are enabled), not to any anti-CD40 binding molecule.

Applicants further note that the presently claimed agonist anti-CD40 antibodies are defined by particular structural and functional characteristics that are fully supported by the present disclosure, as well as the disclosure of the priority application. Specifically, the present claims are drawn to methods of using anti-CD40 antibodies that

(1) bind to CD40 on antigen presenting cells (APC), (2) do not block binding of CD40L to CD40, and (3) induce APC-mediated CTL responses upon binding to CD40. As would be more than apparent to one of ordinary skill based Applicants disclosure and the working Examples described therein (and in the priority application), Applicants clearly had possession of the claimed invention at the time of filing. Moreover, based on the level of skill in the art at the time of the present invention with respect to antibody binding assays and functional T cell studies, as well as the guidance provided in Applicants' disclosure, one of ordinary skill in the art could have made and selected antibodies that bind to CD40 on APCs and induce CTL responses as claimed without undue experimentation (see e.g., pages 9-10, and pages 16-17). Accordingly, Applicants respectfully submit that the previous rejections under 112, first paragraph, are moot.

***Rejections under 35 U.S.C. §112, second paragraph***

Claims 1-16 have been rejected as being indefinite based on the term "APC," which the Examiner asserts should be spelled out, based on the term "non-professional APCs," which the Examiner asserts is ambiguous, and for lacking proper antecedent basis for various terms or phrases.

Applicants respectfully disagree. However, to expedite prosecution, claims 1-16 have been cancelled. Moreover, new claims 21-30 spell out the term "APC", do not contain the term "non-professional APCs," and contain proper antecedent basis. Accordingly, these rejections are now moot.

Claims 12, 13 and 16 have been rejected as being indefinite based on the use of the trade name "Deimmunized<sup>TM</sup>". Specifically, the Examiner asserts that "[t]he claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product." (Paper No. 7, page 10).

Claims 12, 13 and 16 have been cancelled. Therefore, the rejection is moot as applied to these claims.

Applicants respectfully traverse this rejection as it may apply to new claim 24, which also contains the term "Deimmunized™". As stated in the M.P.E.P. 608.01(v):

Names used in trade are permissible in patent applications if:

(A) Their meanings are established by an accompanying definition which is sufficiently precise and definite to be made part of the claim, or

(B) In this country, their meanings are well-known and satisfactorily defined in the literature.

In the instant specification, the term "DEIMMUNIZED™" is accompanied by a precise definition. In particular, this term is defined as referring to "antibodies in which the potential T cell epitopes have been eliminated." (page 8, lines 10-14). In addition, the specification cites International Patent Application PCT/GB98/01473 (WO 98/52976, published Nov. 26, 1998) which describes in detail the technology for making DEIMMUNIZED™ antibodies. Accordingly, the meaning of DEIMMUNIZED™ was well-known and well-defined in the literature at the time of filing.

For at least the foregoing reasons, Applicants respectfully submit that the use of the trade name DEIMMUNIZED™ is permissible in the presently pending claims and therefore request reconsideration and withdrawal of this rejection.

#### ***Rejections under 35 U.S.C. §102***

(I) Claims 1-6, 9 and 15 have been rejected as being anticipated by Caux *et al.* (Research Immunology 145:235-239, 1994). Specifically, the Examiner asserts that "Caux *et al.* teach functional CD40 on B lymphocytes and dendritic cells, and that anti-CD40 antibodies can activate human progenitor and mature lymphocytes and dendritic cells." The Examiner further states that "[t]he prior art agonist anti-CD40 antibodies would have had the inherent property of binding to and stimulating professional and non-professional antigen presenting cells, including dendritic cells as well as induce maturation of dendritic cells." (Paper No. 7, page 11)

Applicants respectfully traverse this rejection. However, to expedite prosecution, claims 1-6, 9 and 15 have been cancelled. Therefore, the rejection is moot as applied to these claims.

New claims 21-30 are drawn to methods of inducing cytotoxic T cell (CTL) responses using anti-CD40 antibodies (or antigen binding fragments thereof) that do not block binding of CD40L to CD40 antigen presenting cells (APCs), such that the antibody induces an APC-mediated antigen specific CTL response in the presence of cytotoxic lymphocytes. The use of such agonistic, non-blocking anti-CD40 antibodies is neither taught nor suggested by Caux et al.

In the studies described by Caux *et al.*, B cell precursors were cultured *in vitro* with soluble anti-CD40 antibodies, in combination with either anti-IgM antibodies or phorbol esters, to examine the effect of these molecules on B cell proliferation (see p.236). In contrast, the present claims are directed to methods for inducing cytotoxic T cell (CTL) responses. Caux *et al.* do not teach or suggest a method of inducing an APC-mediated CTL cell response, let alone using a non-blocking anti-CD40 antibody, as claimed by Applicants.

Accordingly, the present claims are not anticipated by the teachings of Caux *et al.*, and reconsideration and withdrawal of this rejection is respectfully requested.

(II) Claims 1-6, 9 and 12-16 have been rejected as being anticipated by Armitage *et al.* (U.S. Patent No. 5,674,492) on the ground that Armitage *et al.* teach agonistic anti-CD40 antibodies, anti-CD40 antibodies that inhibit binding of CD40 to CD40L, and the use of combinations of antibodies. (Paper No. 7, pages 11-12)

Applicants respectfully traverse this rejection. However, to expedite prosecution, claims 1-6, 9 and 12-16 have been cancelled. Therefore, the rejection is moot as applied to these claims.

New claims 21-30 are drawn to methods of inducing cytotoxic T cell (CTL) responses using anti-CD40 antibodies (or antigen binding fragments thereof) that do not block binding of CD40L to CD40 antigen presenting cells (APCs), such that the antibody induces an APC-mediated antigen specific CTL response in the presence of cytotoxic lymphocytes. The use of such agonistic, non-blocking anti-CD40 antibodies is neither taught nor suggested by Armitage et al.

Contrary to the Examiner's assertion Armitage *et al.* teach the use of antagonistic anti-CD40 antibodies, HuCD40-M2 and HuCD40-M3, alone and in combination with soluble CD40L, to treat B cell lymphoma. Moreover, Armitage *et al.* specifically teach that these antibodies block the binding of CD40L to CD40. In contrast, the present claims are drawn to the use of agonistic anti-CD40 antibodies (i.e., antibodies that are capable of inducing APC-mediated CTL responses) that do not block the binding of CD40L to CD40.

Accordingly, the present claims are not anticipated by the teachings of Armitage *et al.*, and reconsideration and withdrawal of this rejection is respectfully requested.

(III.) Claims 1-6, 9 and 12-16 have also been rejected as being anticipated by Fanslow *et al.* (U.S. Patent 5,801,227) as evidenced by Armitage *et al.* Specifically, the Examiner asserts that Fanslow *et al.* teach that agonist anti-CD40 antibodies existed in the prior art (see column 1 Background of the Invention), and that these antibodies "would have had the inherent property of binding to and stimulating professional and non-professional antigen presenting cells, including dendritic cells as well as induce maturation of dendritic cells."

Applicants respectfully traverse this rejection. However, to expedite prosecution, claims 1-6, 9 and 12-16 have been cancelled. Therefore, the rejection is moot as applied to these claims.

New claims 21-30 are drawn to methods of inducing cytotoxic T cell (CTL) responses using anti-CD40 antibodies (or antigen binding fragments thereof) that do not block binding of CD40L to CD40 antigen presenting cells (APCs), such that the antibody induces an APC-mediated antigen specific CTL response in the presence of cytotoxic lymphocytes. The use of such agonistic, non-blocking anti-CD40 antibodies is neither taught nor suggested by Fanslow et al.

In contrast to the presently claimed invention, Fanslow et al. teach the use of anti-CD40 antibodies, CD40-M2 and CD40-M3, that block binding of CD40L to CD40 in immunoassays to detect CD40 on immune cells. Indeed these are murine forms of the same human antibodies shown to block CD40L binding to CD40 as taught by Armitage

et al.. Moreover, the authors fail to teach or suggest the use of any anti-CD40 antibody, let alone a non-blocking antibody, to induce an APC-mediated antigen specific CTL response, as claimed by Applicants. While Fanslow *et al.* refer to agonistic anti-CD40 antibodies as a means of distinguishing their discovery from the prior art, they do not teach or suggest the use of such antibodies to induce CTL responses.

Accordingly, the teachings of Fanslow *et al.* do not anticipate the presently claimed invention, and reconsideration and withdrawal of this rejection is respectfully requested.

(IV) Claims 1-4, 6 and 9 have been further rejected as being anticipated by Zhou *et al.* (Hybridoma 18:471-478, 1999) on the ground that this reference teaches agonist anti-human CD40 monoclonal antibodies that induce dendritic cell formation and maturation.

Applicants respectfully traverse this rejection. However, to expedite prosecution, claims 1-4, 6 and 9 have been cancelled. Therefore, the rejection is moot as applied to these claims.

New claims 21-30 are drawn to methods of inducing cytotoxic T cell (CTL) responses using anti-CD40 antibodies (or antigen binding fragments thereof) that do not block binding of CD40L to CD40 antigen presenting cells (APCs), such that the antibody induces an APC-mediated antigen specific CTL response in the presence of cytotoxic lymphocytes. The use of such agonistic, non-blocking anti-CD40 antibodies is neither taught nor suggested by Zhou et al.

In contrast to the presently claimed invention, Zhou *et al.* teach that particular anti-CD40 antibodies, such as 5C11, that block CD40L binding to CD40, can promote the proliferation and differentiation of adherent blood monocytes into functional dendritic cells *in vitro*. Indeed, the 5C11 antibody used in their assays was shown to have the same binding characteristics as the commercially available monoclonal antibody MAb89 (see p. 471, column 2, and p. 471, column 1, paragraph entitled “Charactization of MAb”) that had been previously shown to completely block binding of CD40L to CD40 (see Bjorck *et al.*, Appendix B).

Zhou *et al.* do not teach or suggest the use of a non-blocking anti-CD40 antibody, let alone the use of a non-blocking antibody to induce an APC-mediated CTL response, as claimed by Applicants. Indeed, the studies performed by Zhou *et al.* were not even performed in the presence of cytotoxic T cells. Moreover, since Zhou *et al.* taught the use of blocking anti-CD40 antibodies (e.g., 5C11) as CD40 agonists, the authors in fact teach away from the presently claimed invention which is drawn to the use of non-blocking anti-CD40 antibodies as CD40 agonists.

Accordingly, reconsideration and withdrawal of this rejection is respectfully requested.

(V) Claims 1-9 and 12 have been rejected as being anticipated by Katira *et al.* (*Leukocyte Typing V*, Schlossman *et al.* (Ed.), Oxford University Press, Oxford 1995, page 554) on the ground that antibodies taught by Katira *et al.* would inherently have the functional limitations of the agonist anti-CD40 antibodies used in the instant invention.

Applicants respectfully traverse this rejection. However, to expedite prosecution, claims 1-9 and 12 have been cancelled. Therefore, the rejection is moot as applied to these claims.

New claims 21-30 are drawn to methods of inducing cytotoxic T cell (CTL) responses using anti-CD40 antibodies (or antigen binding fragments thereof) that do not block binding of CD40L to CD40 antigen presenting cells (APCs), such that the antibody induces an APC-mediated antigen specific CTL response in the presence of cytotoxic lymphocytes. The use of such agonistic, non-blocking anti-CD40 antibodies is neither taught nor suggested by Katira *et al.*

As with the cited references discussed above, Katira *et al.* fail to teach or suggest the use of a non-blocking anti-CD40 antibody to induce an APC-mediated CTL response, as claimed by Applicants. Indeed, the authors merely performed B cell proliferation studies using various anti-CD40 antibodies that bind to co-operative epitopes.

Accordingly, Katira *et al.* fail to anticipate the presently claimed invention and withdrawal of this rejection is respectfully requested.

***Claim Rejections under 35 U.S.C. §103***

(I) Claims 1-9 and 12-16 have been rejected as being unpatentable over Fanslow *et al.* and/or Armitage *et al.* and/or Zhou *et al.* and/or Caux *et al.* and/or Katira *et al.* in view of “the well known use of chimeric, humanized, DeImmunized, human antibodies at the time the invention was made, as acknowledged on page[s] 6-9 of the instant specification.” Specifically, the Examiner asserts that “Fanslow *et al.*, Armitage *et al.*, Zhou *et al.* and Caux *et al.* differ from the claimed invention by not disclosing the well known use of DeImmunized and human antibodies at the time the invention was made” and “by not exemplifying combination anti-CD40 antibodies.”

Applicants respectfully traverse this rejection. As discussed above, none of the cited references of Fanslow *et al.*, Armitage *et al.*, Zhou *et al.*, Caux *et al.*, or Katira *et al.* teach or suggest that a non-blocking anti-CD40 antibody can be used as an agonist, i.e., to induce an APC-mediated CTL responses. Therefore, even if these references were combined in the manner suggested by the Examiner, they would not even support a *prima facia* case of obviousness.

Indeed, the presently claimed invention was entirely unobvious in view of the teachings of the prior art. Specifically, the few non-blocking anti-CD40 antibodies taught in the prior art has either not been tested for their ability to induce CTL responses (as they would not have thought to have been agonistic since they did not mimic CD40L binding and stimulation which was believed to be required for agonistic effects), or they had been shown to be antagonists to CD40/CD40L mediated immune responses. For example, non-blocking mAb 5D12, described by DeBoer *et al.*, had been shown to be antagonistic (i.e., it inhibited CTL responses), not agonistic. Therefore, it would not have been remotely obvious that a non-blocking anti-CD40 antibody could act as a CD40 agonist, as presently claimed.

Similarly, most of the known agonistic anti-CD40 antibodies that had been characterized in the prior art had been shown to be blocking antibodies (not non-blocking antibodies, as presently claimed), such as mAb 5C11 taught by Zhou *et al.*, MAb89 taught by Bjorck *et al.* (submitted herewith as Appendix B). Thus, in view of the teachings of these references, one of ordinary skill in the art at the time of the invention

trying to generate an agonistic anti-CD40 antibody would have been motivated to generate a blocking anti-CD40 antibody, since it was thought that the agonistic effect was provided by simulating the stimulatory signal provided by CD40L.

Accordingly, Applicants' discovery that non-blocking anti-CD40 antibodies are capable of agonizing CTL responses was entirely unexpected over the teachings of the cited references, as well as other anti-CD40 antibodies known in the prior art. In addition, the use of non-blocking anti-CD40 antibodies provides a significant advantage in that it does not prevent natural CD40L-mediated immune responses from occurring. Thus, the claimed method of inducing a CTL response can be used as an additive therapy in the presence of CD40L, but also can stimulate CTL responses (i.e., be used therapeutically) in the absence of CD40L.

As previously discussed, prior to the present invention, those skilled in the art recognized two ways in which cytotoxic T cells could be activated: by dendritic cells presenting antigen in the presence of helper T cells, or by virally infected dendritic cells expressing large amounts of antigen bound to MHC class I on their cell surface. In contrast, the present invention is based on the surprising finding that agonist anti-CD40 antibodies that do not block binding of CD40L to CD40 are particularly effective at inducing CTL responses, even in the absence of either T helper cells or virally infected dendritic cells.

For at least the foregoing reasons, Applicants respectfully request reconsideration and withdrawal of this rejection.

(II) Claims 7-16 have been rejected as being unpatentable over Fanslow *et al.* and/or Armitage *et al.* and/or Zhou *et al.* and/or Caux *et al.* and/or Katira *et al.* in view of "the well known use of chimeric, humanized, DeImmunized, human antibodies at the time the invention was made, as acknowledged on page[s] 6-9 of the instant specification, and further in view of Ledbetter *et al.* (U.S. Patent No. 6,132,992), Chang *et al.* (U.S. Patent No. 6,106,835) and Heath *et al.* (Eur. J. Immunol. 24:1828-1834, 1994).

Applicants respectfully traverse this rejection. As discussed above, the combination of Fanslow *et al.*, Armitage *et al.*, Zhou *et al.*, Caux *et al.* and/or Katira *et*

*al.* fail to teach, suggest, or in any way render the presently claimed invention obvious. Ledbetter *et al.* (U.S. Patent No. 6,132,992), Chang *et al.* (U.S. Patent No. 6,106,835) and Heath *et al.* (Eur. J. Immunol. 24:1828-1834, 1994) fail to make up for the above-discussed deficiencies.

Ledbetter *et al.* generally discusses bispecific antibodies that bind to a long list of possible antigens, including CD40. Chang *et al.* teach bispecific antibodies that are specific for T or B cell surface antigens CD3, TCR, CD4 and CD8, but make no mention of CD40. Heath *et al.* and Katira *et al.* teach anti-CD40 antibodies that bind to distinct epitopes. None of these references, alone or in combination, teach or suggest the use of an agonistic, non-blocking, anti-CD40 antibody, or bispecific antibody containing such an antibody, capable of inducing an APC-mediated CTL response, as presently claimed. Moreover, the use of such bispecific antibodies would have been entirely unobvious for all of the reasons described above.

Accordingly, at least for the foregoing reasons, reconsideration and withdrawal of this rejection is respectfully requested.

**SUMMARY**

In view of the remarks set forth above, it is respectfully submitted that this application is in condition for allowance. If there are any remaining issues or the Examiner believes that a telephone conversation with Applicants' Attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned at (617) 227-7400.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Cynthia L. Kanik, Ph.D.

Reg. No. 37,320

Attorney for Applicants

Date: October 10, 2003  
28 State Street  
Boston, MA 02109  
(617) 227-7400  
(617) 742-4214